TEL AVIV — A single recording of the Covid-19 vaccine developed by Pfizer Inc. and BioNTech SE was developed, is 85% effective in preventing symptomatic diseases 15 to 28 days after administration, an Israeli study found, a development that could help policymakers determine vaccine priorities worldwide.
Some governments are debating whether to delay the second inclusion of the recommended two-dose regimen to make optimal use of the vaccine shortage.
The Israeli study, conducted by the government-run Sheba Medical Center and released on Friday, also found a 75% reduction in all Covid-19 infections, symptomatic or asymptomatic, after the first shot. The peer-reviewed study was published in the British medical journal Lancet as a correspondence, meaning that it represents the views of the authors and not the journal.
The data used were collected about the 9109 health workers of the center, who began their vaccination process on December 19th.
“This is the first study that assesses the effectiveness of a single dose of vaccine in real conditions and shows that the early efficacy is even before the second dose has been administered,” said prof. Eyal Leshem, director of Sheba’s Center for Travel Medicine and Tropical Diseases and one said. of the authors of the study.